NCT02419287View on ClinicalTrials.gov

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions
DRUG

crizotinib

Trial Locations (1)

20900

ASST-Monza, Monza

All Listed Sponsors
lead

University of Milano Bicocca

OTHER

NCT02419287 - Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | Biotech Hunter | Biotech Hunter